Jas Hundal

Jas Hundal is an experienced finance professional currently serving as Senior Director Finance at Alpha-9 Oncology since April 2023. Prior to this role, Jas held the position of Chief Financial Officer at Symvivo Corporation from March 2022 to February 2023. Jas has a strong background in strategic and commercial finance, having worked as Director at Zymeworks Inc. from July 2016 to March 2022, where responsibilities included both strategic & commercial finance and corporate finance and FP&A. Additionally, Jas contributed as a Board Observer at Innovakine Therapeutics between March 2020 and September 2021. Early career experiences include roles as Controller for FP&A and MD&A at TELUS from 2009 to July 2016, Manager of Financial Planning & Analysis at Exelixis in 2008-2009, and significant tenure at KPMG in various positions, culminating in Audit Manager between 2002 and 2007.